N-Acetyl Semax Amidate
Nootropic
Also known as: NA Semax Amidate, NASA, Ac-MEHFPGP-NH2, N-acetyl semax amidate
Either documented serious adverse events in humans, or effectively no retrievable evidence base. Dosing figures circulating for these compounds have no scientific foundation.
No primary pharmacokinetic study located for the acetylated/amidated analog. Vendor claims of an 'extended half-life' (e.g. '~30 min longer than Semax' or '2-10 h') are extrapolations from the known chemistry (N-acetylation blocks aminopeptidases, C-amidation blocks carboxypeptidases) and are NOT backed by a measured PK study, treat as unverified.
No primary-sourced dose. This is a research-chemical variant with no clinical registration; all dosing guidance is vendor/community-derived. Typically used intranasally.
No peer-reviewed PK or efficacy studies found for the acetylated-amidated form specifically. Human data absent; mechanistic claims are inferred from parent Semax.
Lyophilised: General peptide convention: -20 C lyophilized (no compound-specific data).
Reconstituted: General convention: 2-8 C refrigerated (no compound-specific data).
Unstudied modified analog; no safety data. Longer duration is theoretical, which could also prolong any adverse effects. Not for human use per regulators.